$3.56
+0.02
(+0.57%)▲
1.12%
Downside
Day's Volatility :5.88%
Upside
4.81%
1.97%
Downside
52 Weeks Volatility :48.48%
Upside
47.44%
Period | Cosciens Biopharma Inc | Index (Russel 2000) |
---|---|---|
3 Months | -42.35% | 0.0% |
6 Months | -42.35% | 0.0% |
1 Year | -42.35% | 0.0% |
3 Years | -42.35% | -25.0% |
Market Capitalization | 13.1M |
Book Value | $8.57 |
Earnings Per Share (EPS) | -2.69 |
Profit Margin | 0.0% |
Operating Margin TTM | -160.68% |
Return On Assets TTM | -23.34% |
Return On Equity TTM | -65.92% |
Revenue TTM | 4.9M |
Revenue Per Share TTM | 3.76 |
Quarterly Revenue Growth YOY | 4.1000000000000005% |
Gross Profit TTM | 0.0 |
EBITDA | -18.0M |
Diluted Eps TTM | -2.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Sell
Neutral
Buy
Cosciens Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cosciens Biopharma Inc | -6.84% | -42.35% | -42.35% | -42.35% | -42.35% |
Regeneron Pharmaceuticals, Inc. | -19.94% | -7.23% | 5.93% | 31.14% | 169.97% |
Biontech Se | -5.69% | 25.74% | 21.03% | -58.77% | 584.62% |
Alnylam Pharmaceuticals, Inc. | -3.43% | 77.77% | 69.8% | 60.25% | 192.92% |
Vertex Pharmaceuticals Incorporated | 1.32% | 18.36% | 28.88% | 156.73% | 136.88% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cosciens Biopharma Inc | NA | NA | NA | 0.0 | -0.66 | -0.23 | NA | 8.57 |
Regeneron Pharmaceuticals, Inc. | 24.57 | 24.57 | 1.27 | 44.77 | 0.17 | 0.08 | NA | 261.41 |
Biontech Se | 160.8 | NA | 0.04 | -2.76 | -0.03 | -0.02 | NA | 80.22 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.39 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.16 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cosciens Biopharma Inc | NA | $13.1M | -42.35% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $102.2B | 169.97% | 24.57 | 32.04% |
Biontech Se | Buy | $27.1B | 584.62% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 192.92% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $122.6B | 136.88% | 32.84 | -4.74% |
æterna zentaris inc. (tsx: aez, nasdaq: aezs) is a global biopharmaceutical company focused on endrocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. æterna zentaris inc. (tsx: aez, nasdaq: aezs) est une société biopharmaceutique internationale, spécialisée dans la découverte, le développement et la commercialisation de thérapies en endocrinologie et en oncologie.
Organization | Cosciens Biopharma Inc |
Employees | 0 |
CEO | Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc. |
Industry | Miscellaneous |
Victoryshares International
$3.56
+0.57%
Clearbridge Focus Value Esg Etf
$3.56
+0.57%
Citizens & Northern Corp
$3.56
+0.57%
Pgim Jennison Focused Growth Etf
$3.56
+0.57%
Israel Acquisitions Corp
$3.56
+0.57%
Foremost Lithium Resource & Technology Ltd
$3.56
+0.57%
Blackrock Etf Trust Long Term Us Eqt
$3.56
+0.57%
Overlay Shares Shrt Term Bon
$3.56
+0.57%
Central Puerto Sa
$3.56
+0.57%